Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Derm Venereol ; 103: adv14153, 2023 Oct 06.
Article in English | MEDLINE | ID: mdl-37800349

ABSTRACT

The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) registry was initiated to prospectively determine the long-term impairment caused by chronic inflammatory dermatoses on patients' lives. The study included 88 patients starting baricitinib for treatment of atopic dermatitis. Clinical evaluation and patient-reported outcomes were recorded at baseline and after 6 and 12 months. After 6 months and 1 year of follow-up, 65 and 47 patients, respectively, were still being treated with baricitinib. Treatment failure was the main reason for discontinuation. Only 1 patient stopped baricitinib because of a side-effect. After 1 year of follow-up, the mean Eczema Area and Severity Index score decreased significantly from 20.7 to 6.4; the percentage of patients with severe atopic dermatitis decreased from 42.9% to 6.5% and a significant improvement in most patient-reported outcomes was noted. There was no difference in terms of efficacy whether or not patients were previously treated with dupilumab. The results remained stable after 6 and 12 months of treatment, which suggests a sustained efficacy of the treatment in patients who initially responded well.


Subject(s)
Azetidines , Dermatitis, Atopic , Humans , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/drug therapy , Quality of Life , Azetidines/adverse effects , Registries , Treatment Outcome , Severity of Illness Index , Double-Blind Method
2.
Emerg Infect Dis ; 25(12): 2197-2204, 2019 12.
Article in English | MEDLINE | ID: mdl-31742503

ABSTRACT

Zoonotic transmission of parapoxvirus from animals to humans has been reported; clinical manifestations are skin lesions on the fingers and hands after contact with infected animals. We report a human infection clinically suspected as being ecthyma contagiosum. The patient, a 65-year-old woman, had 3 nodules on her hands. She reported contact with a sheep during the Aïd-el-Fitr festival in France during 2017. We isolated the parapoxvirus orf virus from these nodules by using a nonconventional cell and sequenced the orf genome. We identified a novel orf virus genome and compared it with genomes of other orf viruses. More research is needed on the genus Parapoxvirus to understand worldwide distribution of and infection by orf virus, especially transmission between goats and sheep.


Subject(s)
Ecthyma, Contagious/diagnosis , Ecthyma, Contagious/virology , Genome, Viral , Orf virus/genetics , Biopsy , DNA, Viral , Ecthyma, Contagious/epidemiology , Ecthyma, Contagious/history , France/epidemiology , History, 21st Century , Humans , Orf virus/classification , Orf virus/isolation & purification , Orf virus/ultrastructure , Phylogeny , Polymerase Chain Reaction , Population Surveillance , Whole Genome Sequencing
SELECTION OF CITATIONS
SEARCH DETAIL
...